Basal cell carcinoma
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
A na-achọpụta ọnya ọnya na-emetụta akpụkpọ imi n'ime onye agadi dị ka Basal cell carcinoma. Imi bụ ebe a na-ahụkarị maka ụdị ọrịa kansa anụ ahụ.
Basal cell carcinoma nwere ike ịpụta na oke na ọnya oge niile.
Enwere ike chefuo Basal cell carcinoma wart.
References
Basal cell carcinoma (BCC) bụ ụdị ọrịa kansa anụ ahụ na-ahụkarị. Ikpughe ìhè anyanwụ bụ isi ihe kpatara ya. Ihe fọrọ nke nta ka ọ bụrụ ikpe BCC niile na-egosi akara Hedgehog na-emebiga ihe ókè na nyocha nke mkpụrụ ndụ ihe nketa. A na-enweta ọgwụgwọ dị iche iche ma họrọ dabere n'ihe ize ndụ nlọghachi azụ, mkpa nke nchekwa anụ ahụ, mmasị ndị ọrịa, na oke ọrịa.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas bụ ụdị ọrịa kansa anụ ahụ na-ahụkarị n'etiti ndị toro eto nwere akpụkpọ ahụ nke dị afọ 50 na karịa. Ọnụ ọgụgụ ha na-arị elu n'ụwa niile, ọkachasị n'ihi ikpughe na ìhè anyanwụ. Ụfọdụ ọnọdụ mkpụrụ ndụ ihe nketa nwere ike ime ka ndị mmadụ nwee ike ịmalite ịmalite ọrịa cancer ndị a mgbe ha ka dị obere. Basal cell carcinomas dịgasị iche n'ịdị njọ, sitere na ọnya elu ma ọ bụ nodular enwere ike ịgwọta ngwa ngwa ruo nke ukwuu nke chọrọ mkparịta ụka n'ime ndị otu ahụike pụrụ iche. Amụma na-adabere na ohere nke ọrịa kansa na-alọghachi ma ọ bụ ike ya imebi anụ ahụ dị nso. Ịwa ahụ bụ ọgwụgwọ ọkọlọtọ maka ọtụtụ ikpe, na-ahụ na mwepụ nke ọma na ohere dị ala nke nlọghachi. Ụzọ ndị na-adịghị emerụ ahụ nwere ike ịgwọ ọnya elu nke ọma.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Ọgwụgwọ mbụ maka BCC bụ ịwa ahụ. Maka BCC nwere nnukwu ihe ize ndụ ma ọ bụ ugboro ugboro, ọkachasị na mpaghara dị oke egwu, a na-akwado ịwa ahụ nke ejiri micrographically achịkwa. Ndị ọrịa nwere BCC nwere obere ihe ize ndụ nwere ike ịtụle ọgwụgwọ mpaghara ma ọ bụ ụzọ mbibi. Usoro ọgwụgwọ fotodynamic na-arụ ọrụ nke ọma maka BCC nodular dị elu yana obere ihe ize ndụ. Maka BCC dị elu ma ọ bụ metastatic, a na-akwado ndị na-egbochi Hedgehog (vismodegib, sonidegib) . Ọ bụrụ na enwere ọganihu ọrịa ma ọ bụ anabataghị ndị na-egbochi Hedgehog, enwere ike ịtụle immunotherapy na anti-PD1 antibody (cemiplimab) . Radiotherapy bụ ezigbo nhọrọ maka ndị ọrịa na-enweghị ike ịwa ahụ, karịsịa ndị ọrịa agadi. Enwere ike ịtụle electrochemotherapy ma ọ bụrụ na ịwa ahụ ma ọ bụ redio abụghị nhọrọ.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Ihe ndị dị ize ndụ gụnyere ikpughe na ìhè ultraviolet, ọgwụgwọ radieshon, ikpughe ogologo oge na arsenic na arụ ọrụ sistemu na-adịghị mma (dịka ntụgharị akụkụ ahụ). Ikpughe ọkụ UV n'oge nwata na-emerụ ahụ nke ukwuu.
Mgbe achọpụtara ya site na biopsy, ọgwụgwọ na-abụkarị site na ịwa ahụ. Nke a nwere ike ịbụ site na mwepu dị mfe ma ọ bụrụ na ọrịa kansa dị ntakịrị; Ọ bụrụ na ọrịa kansa adịghị obere, a na-atụ aro ịwa ahụ Mohs.
Basal cell carcinoma bụ opekata mpe 32% nke ọrịa cancer niile n'ụwa niile. N'ime ọrịa cancer akpụkpọ anụ ndị ọzọ karịa melanoma, ihe dịka 80% bụ ọrịa cancer basal-cell. Na United States, ihe dị ka 35% nke ndị nwoke ọcha na 25% nke ụmụ nwanyị ọcha na-emetụta basal cell carcinoma n'oge ụfọdụ na ndụ ha.
○ Diagnosis na ọgwụgwọ
#Dermoscopy
#Skin biopsy
#Mohs surgery